4 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
4 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
4 位分析師評估梯瓦製藥行業：你需要知道的
In the latest quarter, 4 analysts provided ratings for Teva Pharmaceutical Indus (NYSE:TEVA), showcasing a mix of bullish and bearish perspectives.
在最近一個季度裏，4位分析師爲Teva Pharmaceutical Indus (NYSE:TEVA)提供了評級，展示了看好和看淡的觀點。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
以下表格概括了他們最近的評級，展示了過去30天內的情緒演變並與之前的幾個月進行了比較。
Insights from analysts' 12-month price targets are revealed, presenting an average target of $18.75, a high estimate of $21.00, and a low estimate of $14.00. This upward trend is evident, with the current average reflecting a 4.17% increase from the previous average price target of $18.00.
從分析師的12個月價格目標中獲得的見解揭示了平均目標爲18.75美元，最高估值爲21.00美元，最低估值爲14.00美元。這一上升趨勢是顯而易見的，當前的平均價格反映了從先前的18.00美元的平均價格目標上升了4.17%。
Breaking Down Analyst Ratings: A Detailed Examination
分析師評級分析：詳細分析
The standing of Teva Pharmaceutical Indus...
通過對最近分...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。